Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: Ancillary findings from the SU.FOL.OM3 randomized trial

American Journal of Clinical Nutrition

Volumn 94, Issue 1, 2011, Pages 278-286

  Andreeva, Valentina A ^a   Kesse Guyot, Emmanuelle ^a   Barberger Gateau, Pascale ^b   Fezeu, Léopold ^a   Hercberg, Serge ^a,c   Galan, Pilar ^a  

^a University of Paris XIII ^*  (France)

^b INSERM   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PYRIDOXINE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; DOUBLE BLIND PROCEDURE; FEMALE; FRANCE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; ORIENTATION; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SEX; TASK PERFORMANCE; UNSTABLE ANGINA PECTORIS; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; COGNITION; DEMENTIA; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; FOLIC ACID; HUMANS; MALE; MIDDLE AGED; STROKE; VITAMIN B 12; VITAMIN B 6;

ANGINA;

EID: 79959449537     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.110.006320     Document Type: Article

References (46)

1. World Health Organization. Active ageing: a policy framework. Geneva, Switzerland: World Health Organization, 2002.
2. Coley N, Andrieu S, Gardette V, et al. Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev 2008;30:35-66.
3. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010;6:158-94.
4. World Health Organization. Alzheimer's disease: the brain killer. Geneva, Sitzerland: World Health Organization, 2001.
5. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 2000;903:457-65.
6. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann N Y Acad Sci 2000;903:411-23. (Pubitemid 30251583)
7. de la Torre JC. Alzheimer's disease is incurable but preventable. J Alzheimers Dis 2010;20:861-70.
8. van Goor L, Woiski MD, Lagaay AM, Meinders AE, Tak PP. Review: cobalamin deficiency and mental impairment in elderly people. Age Ageing 1995;24:536-42.
9. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32. (Pubitemid 30466029)
10. Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005;82:636-43.
11. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 2002;22:1752-62. (Pubitemid 35386293)
12. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Vitamin B12 and folate depletion in cognition: a review. Neurol India 2004;52:310-8.
13. Smith AD, Refsum H. Vitamin B-12 and cognition in the elderly. Am J Clin Nutr 2009;89:707S-11S.
14. Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, et al. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging 2007;11:132-52. (Pubitemid 46725290)
15. Balk EM, Raman G, Tatsioni A, Chung M, Lau J, Rosenberg IH. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med 2007;167:21-30.
16. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007;369:208-16. (Pubitemid 46107683)
17. Jia X, McNeill G, Avenell A. Does taking vitamin, mineral and fatty acid supplements prevent cognitive decline? A systematic review of randomized controlled trials. J Hum Nutr Diet 2008;21:317-36. (Pubitemid 352044725)
18. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008;CD004514.
19. Raman G, Tatsioni A, Chung M, et al. Heterogeneity and lack of good quality studies limit association between folate, vitamins B-6 and B-12, and cognitive function. J Nutr 2007;137:1789-94. (Pubitemid 47037708)
20. Cunnane SC, Plourde M, Pifferi F, Begin M, Feart C, Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 2009;48:239-56.
21. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006;63:1402-8. (Pubitemid 44547551)
22. Yurko-Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010;6:456-64.
23. Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005;4:752-9. (Pubitemid 41457291)
24. Galan P, Kesse-Guyot E, Czernichow S, et al. B-vitamins, n-3 poly-unsaturated fatty acids and risk of cardiovascular events: the SU.FOL. OM3 trial. BMJ 2010;341:C6273.
25. Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S. The SU. FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials 2008;9:35.
26. Galan P, de Bree A, Mennen L, et al. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging 2003;7:428-35. (Pubitemid 37157967)
27. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:111-7. (Pubitemid 20164001)
28. Welsh KA, Breitner JCS, Magruder-Habib KM. Detection of dementia in the elderly using telephone screening of cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:103-10. (Pubitemid 23112862)
29. de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry 2003;18:318-24. (Pubitemid 36503043)
30. Vercambre MN, Cuvelier H, Gayon YA, et al. Validation study of a French version of the modified telephone interview for cognitive status (F-TICS-m) in elderly women. Int J Geriatr Psychiatry 2010;25:1142-9.
31. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
32. Isaacs B, Akhtar AJ. The set test: a rapid test of mental function in old people. Age Ageing 1972;1:222-6.
33. Proust-Lima C, Amieva H, Dartigues JF, Jacqmin-Gadda H. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol 2007;165:344-50. (Pubitemid 46174759)
34. Barber M, Stott DJ. Validity of the Telephone Interview for Cognitive Status (TICS) in post-stroke subjects. Int J Geriatr Psychiatry 2004;19:75-9. (Pubitemid 38180695)
35. Savva GM, Stephan BC; Alzheimer's Society Vascular Dementia Systematic Review Group. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 2010;41:e41-6.
36. Van Dyk K, Sano M. The impact of nutrition on cognition in the elderly. Neurochem Res 2007;32:893-904. (Pubitemid 46481315)
37. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75. (Pubitemid 38500310)
38. Stott DJ, MacIntosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 2005;82:1320-6. (Pubitemid 43779732)
39. Kang JH, Cook N, Manson J, Buring JE, Albert CM, Grodstein F. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr 2008;88:1602-10.
40. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304:1903-11.
41. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1538-44.
42. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n23 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 2010;91:1725-32.
43. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008;71:430-8.
44. Desmond DW, Tatemichi TK, Hanzawa L. The Telephone Interview for Cognitive Status (TICS): reliability and validity in a stroke sample. Int J Geriatr Psychiatry 1994;9:803-7. (Pubitemid 24319425)
45. Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol 2009;66:1210-5.
46. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186-91. (Pubitemid 46825511)